![harpoon therapeutics harpoon therapeutics](https://pharmashots.com/wp-content/uploads/2019/11/Abbvie-14-850x560.jpg)
![harpoon therapeutics harpoon therapeutics](https://finvestmonitor.com/img/ava_user/ipo_tick/HARP.jpg)
Shari About Takeda Pharmaceutical Company Maverick was founded by Jeanmarie Guenot, Ph.D., MPM founder Luke Evnin, Ph.D., and Patrick Baeuerle, Ph.D., an internationally renowned cancer immunologist and an acknowledged leader in the T-cell redirection field. Maverick’s therapeutic antibodies are designed to be inactive upon administration but fully active in the tumor microenvironment. Maverick’s novel T-cell engagement format has the potential to eliminate the toxicity challenges inherent in the use of T-cell redirection therapy due to expression of the target antigen on normal tissue. Maverick was spun out of its former parent, Harpoon Therapeutics, Inc., during 2016. Maverick Therapeutics is a private start-up biotechnology company that had been solely financed by MPM Capital. Takeda signed agreements with Maverick Therapeutics through its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc. The management team of Maverick will be led by President and Chief Scientific Officer Hans-Peter Gerber, Ph.D., formerly of Pfizer. Takeda will add a director to Maverick’s Board.
#Harpoon therapeutics series
MPM’s BioVentures 2014 and the UBS Oncology Impact Fund, managed by MPM Capital, join Takeda in a $23 million Series B Financing as a key element of the financing package. Working together with Maverick will enable us to leverage a potentially groundbreaking biologics platform to support Takeda’s goal of developing innovative, targeted therapies to treat people with cancer.” “Collaborations are critical to helping us advance our aspiration of curing cancer. “We see significant potential in Maverick to develop unique, small and customizable T-cell engagement therapeutics,” said Phil Rowlands, Interim Head, Oncology Therapeutic Area Unit, Takeda. “Importantly, this strong collaboration should allow us to move rapidly to the clinic and address unmet needs in cancer immunotherapy.” “We believe that this collaboration validates Maverick’s approach to T-cell engagement in the tumor microenvironment which we believe will allow us to address previously intractable oncology targets,” said Jeanmarie Guenot, Ph.D., Maverick’s co-founder. The $125 million of funding includes an upfront option, equity and research and development funding payments, and provides Takeda the exclusive right to purchase Maverick after five years for an undisclosed sum. and OSAKA, Japan, JanuMaverick Therapeutics Inc., an MPM Capital portfolio company, and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that they have entered a collaboration to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer.
![harpoon therapeutics harpoon therapeutics](https://ether-assets.ams3.digitaloceanspaces.com/arix/_1200x630_crop_center-center_none/Harpoon-TX.jpg)
Takeda Invests $125 Million in Maverick, Including Exclusive Option-to-AcquireīRISBANE, Calif., CAMBRIDGE, Mass. Collaboration to Develop a Novel Biologics Platform with the Potential to Improve the Therapeutic Utility of T-cell Redirection Therapy for the Treatment of Cancer